Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Jan
05
Today In Oncology
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma
Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo